AR020762A1 - El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas - Google Patents

El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas

Info

Publication number
AR020762A1
AR020762A1 ARP990105115A ARP990105115A AR020762A1 AR 020762 A1 AR020762 A1 AR 020762A1 AR P990105115 A ARP990105115 A AR P990105115A AR P990105115 A ARP990105115 A AR P990105115A AR 020762 A1 AR020762 A1 AR 020762A1
Authority
AR
Argentina
Prior art keywords
carnitine
resveratrol
prevention
aging
produce
Prior art date
Application number
ARP990105115A
Other languages
English (en)
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of AR020762A1 publication Critical patent/AR020762A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un producto farmacéutico que comprende mezclados o envasados separadamente (A) L-carnitina o un alcanoil L-carnitina (por ejemplo, acetil L-carnitina opropionil L-carnitina) y (B) un trihidroxi o tetrahidroxiestilbeno (por ejemplo, resveratrol) es util para la prevencion y el tratamiento de las formaspatologicas debido a trastornos neuronales o cerebrales.
ARP990105115A 1998-10-09 1999-10-08 El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas AR020762A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998RM000636A IT1302365B1 (it) 1998-10-09 1998-10-09 Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali

Publications (1)

Publication Number Publication Date
AR020762A1 true AR020762A1 (es) 2002-05-29

Family

ID=11406160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105115A AR020762A1 (es) 1998-10-09 1999-10-08 El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas

Country Status (27)

Country Link
US (1) US6515020B1 (es)
EP (1) EP1117394B1 (es)
JP (1) JP4166951B2 (es)
KR (1) KR20010079981A (es)
CN (1) CN1323205A (es)
AR (1) AR020762A1 (es)
AT (1) ATE249823T1 (es)
AU (1) AU767492B2 (es)
BR (1) BR9915918A (es)
CA (1) CA2344893C (es)
CZ (1) CZ2001920A3 (es)
DE (1) DE69911441T2 (es)
DK (1) DK1117394T3 (es)
EE (1) EE200100205A (es)
ES (1) ES2207287T3 (es)
HK (1) HK1040935A1 (es)
HU (1) HU229364B1 (es)
IL (1) IL142046A0 (es)
IS (1) IS5896A (es)
IT (1) IT1302365B1 (es)
NO (1) NO20011693L (es)
PL (1) PL197342B1 (es)
PT (1) PT1117394E (es)
SK (1) SK3782001A3 (es)
TN (1) TNSN99186A1 (es)
TR (1) TR200100947T2 (es)
WO (1) WO2000021526A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047193A (ja) * 2000-07-31 2002-02-12 Sunstar Inc アレルギー性皮膚炎予防または治療用組成物
US20020173511A1 (en) * 2000-11-08 2002-11-21 Wurtman Richard J. Serotonergic compositions and methods for treatment of mild cognitive impairment
BRPI0106382B1 (pt) * 2001-03-13 2017-07-11 Universidade Do Estado Do Rio De Janeiro - Uerj Process for obtaining decocts from vitis labrusca and vitis vinifera casts, process for obtaining the hydro-alcoholic extract, process for obtaining the hydro-alcoholic extract-ethyl acetate and pharmaceutical compositions
DE50111204D1 (de) * 2001-08-18 2006-11-23 Cognis Ip Man Gmbh Wirkstoffmischungen
US20070218152A1 (en) * 2002-03-12 2007-09-20 Roberto Moura Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
KR100574392B1 (ko) * 2003-02-07 2006-05-02 재단법인서울대학교산학협력재단 신경보호활성을 갖는 신규 페닐환 유도체 및 이를함유하는 약학 조성물
EP2236131A3 (en) * 2003-07-01 2011-03-02 President and Fellows of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
KR100543056B1 (ko) * 2003-11-07 2006-01-20 (주)네추럴에프앤피 신경세포 보호 활성이 있는 포도씨 추출물을 포함하는뇌질환 예방 및 치료용 조성물
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
ES2245609B1 (es) * 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060121137A1 (en) * 2004-12-07 2006-06-08 Hartle Diane K Muscadine grape pomace in the treatment of intestinal inflammation
CA2595159A1 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
CN101296693B (zh) * 2005-10-26 2012-07-04 花王株式会社 持久力提高剂
FR2898493B1 (fr) * 2006-03-16 2008-08-08 Af Consulting Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
US20120016037A1 (en) * 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
MX2009008022A (es) * 2007-01-26 2009-12-11 Univ Washington Metodos y composiciones para tratar neuropatias.
AT506014A1 (de) * 2007-10-24 2009-05-15 Karl Mag Dr Zehethofer Functional drink
SG10201503032UA (en) 2010-06-16 2015-06-29 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102919943A (zh) * 2012-10-26 2013-02-13 郑全辉 保健饮品-葡藤素
CN103877170B (zh) * 2012-12-19 2015-11-04 中国医学科学院药用植物研究所 一种虎杖的乙酸乙酯提取物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
CH692837A5 (it) * 1997-07-02 2002-11-29 Lisapharma Spa Composizione farmaceutica per uso alimentare, dietetico o medicinale adatta a migliorare l'assorbimento orale dei polifenoli e particolarmente del resveratrolo presenti nell'uva e nei suoi p
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase

Also Published As

Publication number Publication date
PL197342B1 (pl) 2008-03-31
DK1117394T3 (da) 2004-01-26
TR200100947T2 (tr) 2001-07-23
AU767492B2 (en) 2003-11-13
NO20011693D0 (no) 2001-04-04
IT1302365B1 (it) 2000-09-05
KR20010079981A (ko) 2001-08-22
TNSN99186A1 (fr) 2005-11-10
HK1040935A1 (zh) 2002-06-28
BR9915918A (pt) 2001-08-21
SK3782001A3 (en) 2001-10-08
HUP0104021A3 (en) 2003-12-29
PL347209A1 (en) 2002-03-25
NO20011693L (no) 2001-04-04
EP1117394B1 (en) 2003-09-17
CA2344893C (en) 2008-07-29
PT1117394E (pt) 2004-02-27
IL142046A0 (en) 2002-03-10
CN1323205A (zh) 2001-11-21
DE69911441D1 (de) 2003-10-23
HUP0104021A2 (hu) 2002-02-28
JP4166951B2 (ja) 2008-10-15
ITRM980636A1 (it) 2000-04-10
HU229364B1 (en) 2013-11-28
ATE249823T1 (de) 2003-10-15
DE69911441T2 (de) 2004-07-01
ES2207287T3 (es) 2004-05-16
CZ2001920A3 (cs) 2001-08-15
WO2000021526A1 (en) 2000-04-20
AU6121399A (en) 2000-05-01
EE200100205A (et) 2002-06-17
IS5896A (is) 2001-03-16
CA2344893A1 (en) 2000-04-20
JP2002527389A (ja) 2002-08-27
US6515020B1 (en) 2003-02-04
EP1117394A1 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
AR020762A1 (es) El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas
BR9908488A (pt) Composição farmacêutica de topiramato
HN1998000027A (es) Arilsulfonamidas y analagos
BR9910553A (pt) Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
ATE245978T1 (de) Zusammensetzungen enthaltend propionyl-l- carnitine und hydroxyzitronensäure oder pantothensäure
AR032132A1 (es) Composicion farmaceutica que comprende una combinacion de un compuesto de tramadol y una droga anticonvulsiva y uso de la combinacion para preparar un medicamento
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
ES2169197T3 (es) Composicion farmaceutica que comprende una alcanoil l-carnitina en combinacion con un acido graso poliinsaturado de la serie omega-3 para la prevencion y el tratamiento de trastornos del metabolismo de los lipidos.
PT659402E (pt) Composicoes contendo carotenoides e procarotenoides combinados com polifenois para a prevencao de danos devidos a uma producao anormal de radicais livres.
UY26320A1 (es) Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para la preparacion de medicamentos y formas de administracion que contienen esas sales. ley 17164
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ECSP034518A (es) Nuevos retinoides para el tratamiento de enfisema
ES2177843T3 (es) Composiciones que contienen l-carnitina o sus derivados y antioxidan tes.
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
BR0210650A (pt) Tablete, e, uso do mesmo
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
ES2168309T3 (es) Efectos neuroprotectores primario y secundario de la flupirtina en las enfermedades neurodegenerativas.
AR066455A2 (es) Uso de compuestos n-metil-n-[(1r)-1-fenil-2-(3r)-3-hidroxipirrolidin -1-il-=-etil]-2,2-difenilacetamida para producir un medicamento para el tratamiento de emfermedades intestinales no inflamatorias
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BR9912703A (pt) Composição antioxidante, antiprolìfera, compreendendo uma carnitina e um carotenóide
DK0615443T3 (da) Lægemiddel i akut virksom form indeholdende Flurbiprofen og anvendelse deraf
BRPI0417796A (pt) preparado efervescente de uma substáncia básica de efeito medicinal
PT83253B (pt) Processo para a preparacao de p-acilaminobenzamidas